These results suggest new approaches for the study of the G6PD enzyme from T. vaginalis (and of other parasites that present fused proteins), which will facilitate the specific pharmacological objective to improve the efficiency of existing medications for the treatment of trichomoniasis. This evidence concerns the gene G6PD and Trichomonas vaginitis urogenital infection.